Aaron Mulhall
Pulmonary Disease · Elizabethtown, KYNPI 1801113576
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (46.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Intuitive Surgical at 49.7% of the total. Reporting peaked in 2023 at $7,194 and has fallen 92.0% since, to $573 in 2025.
Across 248 payments — averaging $58.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AstraZeneca$3K
- Insmed, Inc.$881
- Boehringer Ingelheim$379
- Grifols USA, LLC$317
- Sunovion Pharmaceuticals Inc.$252
- plus $2K from 33 others
What the payments were for
- Speaking & faculty fees$3,00021%
- Travel & lodging$7185%
- Food & beverage$4,03128%
- Education$6,70146%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $7,175 |
| AstraZeneca | 25 | $3,414 |
| Insmed, Inc. | 45 | $881 |
| Boehringer Ingelheim | 30 | $379 |
| Grifols USA, LLC | 16 | $317 |
| Sunovion Pharmaceuticals Inc. | 15 | $252 |
| GSK | 17 | $244 |
| Johnson & Johnson(2 entities) | 2 | $228 |
| Genentech USA, Inc. | 9 | $156 |
| United Therapeutics Corporation | 8 | $151 |
| Astellas Pharma US Inc | 4 | $127 |
| Mayne Pharma Commercial LLC | 6 | $102 |
| Actelion Pharmaceuticals US, Inc. | 6 | $97 |
| Mylan Specialty L.p. | 6 | $92 |
| Sanofi | 3 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| CSL Behring | 4 | $64 |
| Baxter Healthcare | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $53 |
| Amgen | 3 | $52 |
| Siemens Medical Solutions USA, Inc. | 2 | $45 |
| Galvanize Therapeutics, Inc | 1 | $36 |
| Viatris Specialty LLC | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Tactile Systems Technology Inc | 2 | $33 |
| Boston Scientific | 1 | $33 |
| Bayer | 2 | $31 |
| Merck | 2 | $29 |
| Pfizer | 2 | $28 |
| Philips North America LLC | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Verona Pharma, Inc. | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| Ambu Inc. | 1 | $13 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
| Pulmonx Corporation | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,060
- ION$3,000
- DALIRESP$1,700
- SYMBICORT$1,300
- Monarch Platform$217
How this compares
$14,450 in reported general payments places this provider in the 80th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $492,303 |
| NucalaMepolizumab | 13 | $55,616 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $48,786 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $40,673 |
| Spiriva RespimatTiotropium Bromide | 23 | $12,579 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,144 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $3,363 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $3,223 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,151 |
| Striverdi RespimatOlodaterol Hcl | 12 | $3,042 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $1,980 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,719 |
| Roflumilast | 19 | $677 |
| Azithromycin | 36 | $455 |
| Montelukast Sodium | 53 | $342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Striverdi Respimat | $379 | $514,06884 claims |
| GSKNucala, Trelegy Ellipta, Arnuity Ellipta | $244 | $99,44074 claims |
| AstraZenecaBreztri Aerosphere | $3,414 | $48,78663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Elizabethtown
- William CundiffElizabethtown$11K
- Navin KainiElizabethtown$11K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
- Karim El-KershLouisville$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.